On December 17, 2025 NanOlogy, LLC, a clinical-stage oncology company, reported the appointment of David Arthur as Chief Executive Officer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This appointment reflects a pivotal step in NanOlogy’s commitment to accelerating development of its LSAM drug portfolio including its development program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a devastating pediatric brain cancer with limited treatment options.
David brings over 35 years of pharmaceutical experience spanning product development, strategy, operations, and commercialization. Most recently, as CEO of Salarius Pharmaceuticals, Inc., David built Salarius into a multiproduct clinical stage oncology company and successfully took the company public with a listing on the NASDAQ exchange. Prior to his biotechnology CEO roles, David spent over 20 years in a variety of executive roles with Eli Lilly and Boehringer Ingelheim.
"We believe David is a great addition to the team and will accelerate our existing drug development activities, business development plans, and new drug development programs. NanOlogy has completed clinical trials in 6 solid tumors with our LSAM investigational drugs, and we look forward to identifying development partners to advance these therapies," said H. Paul Dorman, founder and Chairman of NanOlogy. "We are also completing Investigational New Drug enabling studies for the treatment of a rare pediatric brainstem tumor and plan to submit the IND to the Food and Drug Administration in mid-2026. David’s expertise and abilities will strengthen the organization to rapidly advance these programs and identify strategic and financial partners to help execute our strategy."
"I am extremely impressed by the progress NanOlogy has made in drug development and the potential for these intratumoral drugs, along with other local routes of administration like inhalation, to improve treatment outcomes achieved with systemic cancer treatments," said David Arthur. "My goal will be to rapidly build upon this progress and execute a strategy that benefits cancer patients and creates value for shareholders."
(Press release, NanOlogy, DEC 17, 2025, View Source;utm_medium=rss&utm_campaign=nanology-appoints-david-j-arthur-as-chief-executive-officer-to-drive-clinical-development-of-its-large-surface-area-microparticle-lsam-investigational-drug-portfolio [SID1234661505])